MedDataX Logo

ADME Study in Healthy Male Subjects With TA-8995

NCT ID: NCT02408055

Last Updated: 2016-10-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-06-30

Study Completion Date

2015-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study to measure the absorption, metabolism and excretion of a single dose of radiolabelled TA-8995 (10mg) in healthy male subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Absorption, Distribution, Break Down and Elimination and the Safety of 14C-Labeled Tozadenant

NCT02240290

N/A, as Healthy Volunteers
COMPLETED PHASE1

Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults

NCT04833049

Healthy Volunteers
COMPLETED PHASE1

A Study in Healthy Men to Test How BI 1569912 is Processed in the Body

NCT06520553

Healthy
COMPLETED PHASE1

Absorption, Metabolism, and Excretion Study of [14C]-TNP-2092

NCT05074134

Healthy
COMPLETED PHASE1

Absorption, Metabolism, Excretion and Absolute Bioavailability

NCT03250039

Healthy
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dyslipidemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Radiolabelled TA-8995

Group Type EXPERIMENTAL

TA-8995

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TA-8995

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male subjects

Exclusion Criteria

* Clinically significant abnormalities
Minimum Eligible Age

30 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Xention Ltd

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ashley Brooks

Role: PRINCIPAL_INVESTIGATOR

Covance

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Covance Clinical Research Unit Ltd

Leeds, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TA-8995-07

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Mass Balance Study of [14C] TAS-205 in Healthy Volunteers
NCT04825431 COMPLETED PHASE1
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
NCT04493255 COMPLETED PHASE1
Study of the Absorption, Metabolism, and Excretion of [14C]-Ecopipam in Healthy Male Subjects
NCT04881955 COMPLETED PHASE1
A Study of the Absorption, Metabolism, and Excretion of [14C]-AMG 510 Following a Single Oral Dose in Healthy Male Subjects
NCT05578859 COMPLETED PHASE1
A Study Investigating the Movement of Lu AF28996 Into, Through, and Out of the Body of Healthy Men
NCT06337110 COMPLETED PHASE1
RDEA3170 AME Study
NCT01910506 COMPLETED PHASE1
Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants
NCT04454918 COMPLETED PHASE1
Open-Label Absorption, Distribution, Metabolism, Excretion (ADME) and Pharmacokinetics (PK) Following a Single Oral Dose of AZD1236 in Healthy Male Subjects
NCT01007929 TERMINATED PHASE1
A Study in Healthy Men to Find Out How BI 1015550 is Taken up and Handled by the Body
NCT04771286 COMPLETED PHASE1
An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects
NCT04241393 COMPLETED PHASE1
Adsorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled SPD557 in Volunteers
NCT01786876 COMPLETED PHASE1
Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949
NCT02099071 COMPLETED PHASE1
A Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of AK0529
NCT03400995 COMPLETED PHASE1
Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066
NCT00829088 COMPLETED PHASE1
A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects
NCT05119790 COMPLETED PHASE1
Study to Assess Absolute Bioavailability of TAK-935 (OV935) and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]TAK-935 (OV935) in Healthy Male Participants
NCT04992442 COMPLETED PHASE1
Study to Assess the Metabolism, Excretion and Pharmacokinetics of [14C]AZD1981 in Healthy Male Volunteers
NCT01058447 COMPLETED PHASE1
Material Balance Study of TQ-B3525
NCT05675202 UNKNOWN PHASE1
Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002
NCT02044627 COMPLETED PHASE1
TD-1211 IV/Oral Mass Balance Study
NCT01702194 COMPLETED PHASE1
A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers
NCT01711762 COMPLETED PHASE1
Study to Assess the Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Pitolisant in Healthy Male Volunteers
NCT02929342 COMPLETED PHASE1
A Study in Healthy Men to Test How BI 1291583 is Processed in the Body
NCT05833035 COMPLETED PHASE1
A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Olinciguat in Healthy Male Volunteers
NCT03795519 COMPLETED PHASE1
Safety and Pharmacokinetics of Nicotinamide Mononucleotide (NMN) in Healthy Adults.
NCT04910061 COMPLETED NA